Get all premium features to the best stock analysis tool

Finranks

Company

About us

Contact us

[email protected]

Follow us

Instagram
Telegram
LinkedIn

All rights reserved.

Privacy Policy Terms of Conditions

Home
Markets
Screener
News
About

STIM - Neuronetics, Inc. Latest News | Finranks

Home

STIM

N

Neuronetics, Inc. (STIM)

NGM – Real Time Price. Currency in USD

1.29

-0.04 (-3.01%)

At close: Mar 27, 2026, 4:00 PM EDT

1.40

+0.11 (8.53%)

After-hours: Mar 27, 2026, 6:46 PM EDT

Summary
News
Chart
Financial
Dividends
Forecast
Ownership
Profile

Videos

No Data

There is no data to display

Press releases

Neuronetics Reports Fourth Quarter and Full Year 2025 Financial and Operating Results

Neuronetics Reports Fourth Quarter and Full Year 2025 Financial and Operating Results

Total revenue of $41.8 million in Q4 2025, up 86% as reported and 23% on an adjusted pro forma basis versus Q4 2024 Greenbrook clinic revenue of $23.5 million in Q4 2025, up 428% as reported and 37% on an adjusted pro forma basis versus Q4 2024 Continued cash management improvement, with cash provided by operations of $0.9 million in Q4 2025 Expect full year 2026 revenue of between $160 million and $166 million Dan Reuvers appointed as President and Chief Executive Officer, effective March 23, 2026; proven medical device leader with more than 30 years of experience scaling commercial healthcare businesses MALVERN, Pa., March 17, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc., (NASDAQ: STIM) (the “Company” or “Neuronetics”) a vertically integrated, commercial stage, medical technology and healthcare company with a strategic vision of transforming the lives of patients whenever and wherever they need help, with the leading neurohealth therapies in the world, today announced its financial and operating results for the fourth quarter and full year of 2025.

Neuronetics Appoints Dan Reuvers as President and Chief Executive Officer

Neuronetics Appoints Dan Reuvers as President and Chief Executive Officer

Seasoned leader brings more than 30 years of medical device experience, with a proven track record of growing revenue, earnings, and cash flow across multiple publicly traded healthcare companies Seasoned leader brings more than 30 years of medical device experience, with a proven track record of growing revenue, earnings, and cash flow across multiple publicly traded healthcare companies

Neuronetics Announces Selected Preliminary Unaudited Fourth Quarter and Full Year 2025 Financial Results

Neuronetics Announces Selected Preliminary Unaudited Fourth Quarter and Full Year 2025 Financial Results

All values provided represent preliminary unaudited results Fourth quarter 2025 revenue of $41.8 million, representing 86% year-over-year growth on an as reported basis and 23% year-over-year growth on an adjusted pro forma basis Full year 2025 revenue of $149.2 million, representing 99% year-over-year growth on an as reported basis and 15% year-over-year growth on an adjusted pro forma basis Achieved positive operating cash flow of $0.9 million in the fourth quarter 2025 Ended 2025 with total cash of $34.1 million, inclusive of cash, cash equivalents and restricted cash MALVERN, Pa., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc., (NASDAQ: STIM) (the “Company” or “Neuronetics”) a vertically integrated, commercial stage, medical technology and healthcare company with a strategic vision of transforming the lives of patients whenever and wherever they need help, with the leading neurohealth therapies in the world, today announced selected preliminary unaudited financial results for the fourth quarter and full-year 2025.

Neuronetics to Participate at the Piper Sandler 37th Annual Healthcare Conference

Neuronetics to Participate at the Piper Sandler 37th Annual Healthcare Conference

MALVERN, Pa., Nov. 20, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc., (NASDAQ: STIM) (the “Company” or “Neuronetics”) a vertically integrated, commercial stage, medical technology and healthcare company with a strategic vision of transforming the lives of patients whenever and wherever they need help, with the leading neurohealth therapies in the world, today announced that the management team will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on Thursday, Dec. 4, 2025. The fireside chat is scheduled at 12:30 p.m. (ET) the same day. The presentation will be available via the conference portal to registered attendees.